TOS A’ZOLARI PROLAPSINI O‘RGANISHGA KO‘P OMILLI YONDASHUV: POP-Q KLASSIFIKATSIYASINING KLINIK AHAMIYATI
##article.subject##:
POP-Q; xavf omillari; hayot sifati; tos a’zolarining prolapsi; TVI##article.abstract##
Tos a’zolarining prolapsi (TAP) ayollar orasida, ayniqsa postmenopauza davrida, tos tubi disfunktsiyasining eng keng tarqalgan shakllaridan biridir. Ushbu mavzuning dolzarbligi TAPning yuqori tarqalganligi, bemorlarning hayot sifatiga sezilarli ta’siri hamda diagnostika va patologiyaning og‘irlik darajasini baholash usullarini takomillashtirish zarurati bilan belgilanadi. Turli tasniflar mavjud bo‘lishiga qaramay, POP-Q tasnifi prolapsni klinik baholashda eng obyektiv va takrorlanmaydigan vosita bo‘lib qolmoqda.
Mazkur maqolada TAP alomatlariga ega bo‘lgan 130 nafar bemor ishtirokida o‘tkazilgan prospektiv tadqiqot natijalari keltirilgan. Tadqiqotning maqsadi tos a’zolarining prolapsi rivojlanishiga olib keluvchi xavf omillarini — reproduktiv, somatik, anatomik va xulq-atvor jihatlarini — kompleks o‘rganishdan iborat edi. Prolapsning og‘irlik darajasi POP-Q tasnifi asosida baholandi, bu esa ma’lumotlarni standartlashtirish va TAPning rivojlanganlik darajasi bilan xavf omillar majmuasi o‘rtasidagi statistik jihatdan ahamiyatli korrelyatsiyalarni aniqlash imkonini berdi.
Библиографические ссылки
Barber, M.D., Maher, C. (2021). Epidemiology and outcome assessment of pelvic organ prolapse. International Urogynecology Journal, 32(3), 529–539. https://doi.org/10.1007/s00192-020-04646-0
Bump, R.C., Mattiasson, A., Bø, K., Brubaker, L.P., DeLancey, J.O., Klarskov, P., Shull, B.L., Smith, A.R. (2018). The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. American Journal of Obstetrics and Gynecology, 219(1), 10–17. https://doi.org/10.1016/j.ajog.2018.03.023
Dietz, H.P., Shek, K.L. (2018). The quantification of pelvic organ prolapse using 3D/4D ultrasound. Ultrasound in Obstetrics & Gynecology, 51(1), 125–129. https://doi.org/10.1002/uog.18912
Friedman, T., Eslick, G.D., Dietz, H.P. (2018). Risk factors for prolapse recurrence: systematic review and meta-analysis. International Urogynecology Journal, 29(1), 13–21. https://doi.org/10.1007/s00192-017-3420-3
Li, P., Ma, H., Zhang, J., Zhang, Q. (2025). Global trends in prevalence and future projections of pelvic organ prolapse: A 30-year epidemiological study. International Urogynecology Journal, 36, 991–1002. https://doi.org/10.1007/s00192-025-06049-6
Maher, C., Feiner, B., Baessler, K., Schmid, C. (2022). Surgical management of pelvic organ prolapse in women: a short version Cochrane review. Neurourology and Urodynamics, 41(1), 53–63. https://doi.org/10.1002/nau.24841
Swift, S., Tate, S.B., Nicholas, J. (2019). Correlation of symptoms with degree of pelvic organ support in a general population of women: what is pelvic organ prolapse? American Journal of Obstetrics and Gynecology, 220(5), 511.e1–511.e7. https://doi.org/10.1016/j.ajog.2019.01.234
Vergeldt, T.F.M., Weemhoff, M., IntHout, J., Kluivers, K.B. (2018). Risk factors for pelvic organ prolapse and its recurrence: a systematic review. International Urogynecology Journal, 29(5), 711–722. https://doi.org/10.1007/s00192-017-3423-6
Wu, J.M., Vaughan, C.P., Goode, P.S., Redden, D.T., Burgio, K.L., Richter, H.E., Markland, A.D. (2017). Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstetrics & Gynecology, 129(4), 673–680. https://doi.org/10.1097/AOG.0000000000001933
Xu, Y., Xie, S., Zhou, C., Zhu, L., Tong, Y., Muñoz, A., Wu, Y., Li, X. (2025). Time trends in the incidence of pelvic organ prolapse across the BRICS: an age-period-cohort analysis for the GBD 2019. BMC Public Health, 25, 592. https://doi.org/10.1186/s12889-024-21271-5
Zumrutbas, A.E. (2025). Understanding pelvic organ prolapse: A comprehensive review of etiology, epidemiology, comorbidities, and evaluation. Society of International Urology Journal, 6(1), 6. https://doi.org/10.3390/siuj6010006
Zyczynski, H.M., Kenton, K., Richter, H.E., et al. (2020). Pelvic organ prolapse quantification system (POP-Q) in clinical trials: a review. International Urogynecology Journal, 31(5), 853–862. https://doi.org/10.1007/s00192-019-04084-4
